- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Obsidian Therapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.08. | Obsidian Therapeutics Completes Galera Merger And $350 Million Private Placement | 1 | pulse2.com | ||
| 05.08. | Piper Sandler initiates Obsidian Therapeutics stock with overweight | 2 | Investing.com | ||
| 05.08. | Piper Sandler startet Coverage für Obsidian Therapeutics Aktie mit "Overweight" | 1 | Investing.com Deutsch | ||
| 05.08. | RTW Biotech Opp. - Obsidian Therapeutics merges with Galera | 2 | RNS | ||
| OBSIDIAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.08. | Galera Therapeutics, Inc. - 15-12G, Securities registration termination | 1 | SEC Filings | ||
| 03.08. | Obsidian Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 03.08. | Obsidian Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.08. | Obsidian Therapeutics Completes Galera Therapeutics Merger with $350M Private Placement Financing | 2 | Contract Pharma | ||
| 03.08. | Obsidian Therapeutics completes merger with Galera | 1 | Investing.com | ||
| 03.08. | Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million | 440 | Business Wire | • Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors
• Post-transaction cash and cash equivalents... ► Artikel lesen | |
| 31.07. | Galera Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | Galera Therapeutics, Inc. - 8-K, Current Report | 11 | SEC Filings | ||
| 15.05. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 19.04. | Obsidian Therapeutics, Galera Therapeutics Merger Comes With $350M Infusion for Cancer Drug Trials | 3 | MedCity News | ||
| 15.04. | Obsidian Therapeutics, Galera Therapeutics to advance cell therapy following reverse merger | 4 | BioPharma Dive | ||
| 15.04. | Obsidian Therapeutics To Merge With Galera Therapeutics In Reverse Merger | - | RTTNews | ||
| 15.04. | Obsidian Therapeutics to go public via Galera Therapeutics merger | 2 | Investing.com | ||
| 15.04. | Fusion mit Galera Therapeutics: Obsidian Therapeutics strebt Börsengang an | 3 | Investing.com Deutsch |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 49,360 | -0,85 % | CRISPR Therapeutics legt positive Einjahresdaten für Gentherapie CTX310 vor | ||
| NOVOCURE | 15,365 | -0,19 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,037 | -0,10 % | Spero Therapeutics, Inc. - 8-K, Current Report | ||
| PRECISION BIOSCIENCES | 6,690 | 0,00 % | PRECISION BIOSCIENCES INC - 8-K, Current Report | ||
| BOLT BIOTHERAPEUTICS | 3,980 | +5,43 % | Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 resultsCash balance of $18.1 million as of... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Personalentscheidungen / Vorstand/Strategische Unternehmensentscheidung
QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Potenzial trotz Mega-Rallye: Merck & Co. nach 40-%-Rallye: Morgan Stanley zündet den Kursziel-Turbo! | © Foto: Rafael Henrique - SOPA Images via ZUMA Press WireDie Aktie von Merck Sharp & Dohme (MSD) ist 2026 bereits 40 Prozent gestiegen. Doch Morgan Stanley hebt das Kursziel massiv an - und erklärt... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen |
Das Unternehmen OBSIDIAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,080 (+0,49 %) liegt der Kurs bei 16,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OBSIDIAN THERAPEUTICS INC finden Sie auf Wallstreet Online.